The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

The inaugural Excellence in Healthcare Partnerships (EHP) Awards and Networking Evening is taking place at the Grand Connaught Rooms, London at 5pm on 5th February 2026. An evening of discussion, ...

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...

SMC approves targeted therapy for patients with EGFR exon 20 insertion mutations Johnson & Johnson has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Rybrevant (amivantamab ...

MajesTEC-3 study supports teclistamab plus daratumumab SC as potential standard of care Johnson & Johnson has reported groundbreaking results from the phase 3 MajesTEC-3 study, highlighting the ...

Six new treatments aim to improve patient outcomes across key areas Hikma Pharmaceuticals and Celltrion Inc. have signed exclusive licensing agreements to introduce six biosimilar treatments across ...

Positive safety and pharmacokinetic data lay foundation for phase 2 study in 2026 Herantis Pharma has announced positive topline results from its phase 1b trial of HER-096 in people living with ...